Enlivex focuses resources on Allocetra Phase 2b knee osteoarthritis trial
ENLV•Enlivex said it will immediately cut costs and wind down non-trial research and development, reducing its workforce by approximately 60% to focus resources on its Phase 2b Allocetra trial. Six-month topline results are expected by mid-2027.
1. Cost cuts and trial focus
Enlivex said it will wind down research and development not related to the trial and reduce its workforce by approximately 60% to substantially lower cash burn. Management salaries will fall 20%, while the CEO’s salary will decline 40%. The Phase 2b trial evaluates Allocetra in patients aged 64 and older with moderate-to-severe age-related primary knee osteoarthritis, with six-month topline results expected by mid-2027.
2. Earlier trial results
Completed Phase 1/2a results showed meaningful improvements in knee pain and function versus placebo at three and six months, with favorable safety.
